Active, not recruitingPhase 2NCT03709680
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Studying Atypical teratoid rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Palbociclib(drug)
- Enrollment
- 128 enrolled
- Eligibility
- 2-20 years · All sexes
- Timeline
- 2019 – 2025
Study locations (30)
- University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- MemorialCare Health System - Long Beach Medical Center, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital and Research Center at Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital, Palo Alto, California, United States
- UCSF Medical Center, San Francisco, California, United States
- University of California San Francisco,, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- UF Health Shands Hospital, Gainesville, Florida, United States
- University of Florida College of Medicine, Gainesville, Florida, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Johns Hopkins All Children's Outpatient Care Center, St. Petersburg, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Children's Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03709680 on ClinicalTrials.govOther trials for Atypical teratoid rhabdoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06465199Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07017816A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Children's National Research Institute
- RECRUITINGPHASE2NCT06622941Study to ONO-4538 in Patients With Rhabdoid TumorOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06193759Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Children's National Research Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD
- RECRUITINGPHASE1NCT05835687Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS TumorsSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06853080Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid TumorsTaipei Medical University